FDA Drug Recalls

Recalls / Class II

Class IID-0172-2021

Product

Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP), 0.5%, 150 mg per 30 mL (5 mg per mL), 30 mL Single Dose Vial (NDC 63323-462-01), packaged as 25 Single Dose Vials per tray (NDC 63323-462-37), Rx only, Fresenius Kabi, Lake Zurich, IL 60047.

Brand name
Sensorcaine
Generic name
Bupivacaine Hydrochloride And Epinephrine Bitartrate
Active ingredients
Bupivacaine Hydrochloride, Epinephrine Bitartrate
Route
Epidural, Retrobulbar
NDCs
63323-460, 63323-465, 63323-467, 63323-464, 63323-466, 63323-462
FDA application
NDA018304
Affected lot / code info
Batch # 6123760, Exp 02/2022

Why it was recalled

Subpotent Drug: Low out-of-specification assay results for the epinephrine component.

Recalling firm

Firm
Fresenius Kabi USA, LLC
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
3 Corporate Dr, N/A, Lake Zurich, Illinois 60047-8930

Distribution

Quantity
4411 trays
Distribution pattern
Nationwide in the USA

Timeline

Recall initiated
2020-12-10
FDA classified
2020-12-22
Posted by FDA
2020-12-30
Terminated
2022-08-25
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0172-2021. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.